|ATCC Launches Custom Cell Lines Funded by The Michael J. Fox Foundation for Parkinson's Research|
|By PR Newswire: Biotechnology|
|Tuesday, 06 September 2016 08:53|
"For over 90 years, ATCC has contributed to scientific breakthroughs through the provision of high-quality biological products and services to researchers all around the world," said Dr. Raymond H. Cypess, ATCC Chairman and CEO. "We are honored to partner with the Michael J. Fox Foundation to help researchers better understand the onset and progression of Parkinson's, develop advanced therapies, and speed progress toward a cure."
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the greatest known genetic cause of Parkinson's disease. A major foci of research is to better understand the pathology caused by such mutations and to develop treatments to address LRRK2 dysfunction.
ATCC's new cell lines are derived from cells of the immune system called macrophages that may play a role in the inflammation associated with Parkinson's. Therefore, these tools may also help researchers better understand the neuroinflammatory process in LRRK2 Parkinson's disease.
ATCC's Michael J. Fox Foundation collection includes a LRRK2 control as well as two mutant LRRK2 cell lines:
"LRRK2 is a priority target for Parkinson's drug development, but we still have much to learn about its role in the disease," said Shalini Padmanabhan, Ph.D., MJFF associate director of research programs. "These cell lines will enable important research that will help us advance our understanding of LRRK2 in Parkinson's and identify new treatments."
About The Michael J. Fox Foundation for Parkinson's Research
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atcc-launches-custom-cell-lines-funded-by-the-michael-j-fox-foundation-for-parkinsons-research-300322862.html
SOURCE American Type Culture Collection